Decision Diagnostics News Today

Keith Berman, 70, of Westlake Village, California, pleaded guilty last December to securities fraud totaling around $28 million. The Justice Department said that from February through December 2020, Berman falsely claimed his Decision Diagnostics company had developed a 15-second test to detect COVID-19 in a finger prick sample of blood when, in reality, no such test existed. "Berman defrauded investors to profit from the pandemic," Nicole Argentieri, head of the Justice Department&#...

Decision Diagnostics (OTCMKTS:DECN – Get Free Report) and Perion Network (NASDAQ:PERI – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk. Earnings & Valuation This table compares Decision […]

Perion Network (NASDAQ:PERI – Get Free Report) and Decision Diagnostics (OTCMKTS:DECN – Get Free Report) are both small-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability. Volatility & Risk Perion Network […]

Former CEO and director of Decision Diagnostics Corp., Keith Berman, pleads guilty to securities fraud, wire fraud, and obstruction of an official proceeding.

Zscaler (NASDAQ:ZS – Free Report) and Decision Diagnostics (OTCMKTS:DECN – Free Report) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Risk & Volatility Zscaler has a beta of 0.85, […]

Decision Diagnostics (OTCMKTS:DECN – Get Rating) and Doximity (NASDAQ:DOCS – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Earnings & Valuation This table compares Decision Diagnostics and Doximity’s revenue, […]

Decision Diagnostics (OTCMKTS:DECN – Get Rating) and Perficient (NASDAQ:PRFT – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Valuation and Earnings This table compares Decision Diagnostics and Perficient’s revenue, […]

Decision Diagnostics (OTCMKTS:DECN – Get Rating) and PROS (NYSE:PRO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Institutional & Insider Ownership 0.0% of Decision Diagnostics shares are […]

To print this article, all you need is to be registered or login on Mondaq.com. In December, the SEC filed a  complaint against Decision Diagnostics and its CEO, Keith Berman, for falsely claiming the company had developed a finger prick blood test that could instantaneously detect COVID-19.  As stated in its complaint, the SEC temporarily suspended trading of Decision Diagnostics securities on April 23, 2020. Now, investors have brought suit as well.  Three instit...

Share this article Share this article NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ("Decision Diagnostics" or the "Company") (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00418, is on behalf of a class consisting of all persons and entities other than Defendants that purch...